Physician
Trident Pain Center LLC
Trident Pain Center LLC was paid $1.83M by Medicaid between Jan 2018 and Nov 2024, across 69 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 27% of everything it billed.
33Billing provider infoTRIDENT PAIN CENTER LLC
N CHARLESTON, SC 29406
N CHARLESTON, SC 29406
33aNPI1801992961assigned 09/16/2006
33bProvider typePain Medicine (Anesthesiology) Physician
28Total paid$1.83M
24GClaims90,857
24DCodes billed69
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Pain Medicine (Anesthesiology) Physician providers in South Carolina
Rank by total paid#1 of 25
Median peer was paid$41K
This provider vs. median44×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 15,326 | $354K | |
| 2019 | 19,068 | $379K | |
| 2020 | 16,123 | $323K | |
| 2021 | 17,195 | $340K | |
| 2022 | 13,421 | $229K | |
| 2023 | 5,022 | $121K | |
| 2024incomplete | 4,702 | $84K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 27% | 16,048 | 14,368 | $496K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 21% | 11,849 | 10,735 | $390K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 4.3% | 4,074 | 3,742 | $78K |
| 64493 | 3.8% | 1,957 | 1,809 | $70K | |
| 80346 | 2.8% | 1,682 | 1,634 | $51K | |
| 80348 | 2.8% | 1,675 | 1,627 | $51K | |
| 80364 | 2.7% | 1,699 | 1,650 | $49K | |
| 80332 | 2.3% | 1,689 | 1,640 | $42K | |
| 64494 | 2.0% | 1,939 | 1,776 | $37K | |
| 80350 | 2.0% | 1,689 | 1,640 | $36K | |
| 80345 | 1.9% | 1,681 | 1,632 | $36K | |
| 80353 | 1.8% | 1,693 | 1,644 | $33K |
57 more codes
| 80324 | 1.6% | 1,698 | $30K | |
| 80320 | 1.6% | 1,698 | $30K | |
| 80355 | 1.5% | 1,682 | $28K | |
| 80366 | 1.5% | 1,687 | $28K | |
| 80360 | 1.5% | 1,697 | $28K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.5% | 598 | $28K |
| 83992 | 1.5% | 1,696 | $27K | |
| 64495 | 1.5% | 1,391 | $27K | |
| 80372 | 1.4% | 1,699 | $26K | |
| 80373 | 1.4% | 1,698 | $26K | |
| 64483 | 1.4% | 474 | $25K | |
| 80359 | 1.1% | 183 | $21K | |
| 64490 | 1.0% | 414 | $19K | |
| 80365 | <1% | 588 | $17K | |
| 99152 | <1% | 2,835 | $15K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 295 | $14K |
| 64484 | <1% | 308 | $9K | |
| 64491 | <1% | 329 | $7K | |
| A4550 | Surgical trays | <1% | 1,972 | $7K |
| 64492 | <1% | 223 | $5K | |
| 80361 | <1% | 256 | $4K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 2,065 | $4K |
| 20552 | <1% | 206 | $4K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,540 | $2K |
| 84403 | <1% | 90 | $2K | |
| 84270 | <1% | 90 | $2K | |
| 64635 | <1% | 12 | $2K | |
| 84146 | <1% | 90 | $2K | |
| 83001 | <1% | 90 | $2K | |
| 82627 | <1% | 90 | $2K | |
| 83002 | <1% | 90 | $2K | |
| 64636 | <1% | 21 | $2K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 24 | $1K |
| 86376 | <1% | 91 | $1K | |
| 27096 | <1% | 53 | $1K | |
| 84481 | <1% | 74 | $974.42 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 74 | $966.19 |
| 82746 | <1% | 73 | $846.32 | |
| 83735 | <1% | 88 | $703.80 | |
| 82728 | <1% | 62 | $687.86 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 342 | $644.61 |
| 84460 | <1% | 90 | $604.32 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,834 | $587.10 |
| 82670 | <1% | 26 | $585.48 | |
| 82607 | <1% | 74 | $553.65 | |
| 84439 | <1% | 73 | $519.08 | |
| 80069 | <1% | 74 | $499.35 | |
| 82962 | <1% | 341 | $492.98 | |
| 82150 | <1% | 74 | $372.79 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 13 | $291.64 |
| 84450 | <1% | 74 | $283.34 | |
| 20610 | <1% | 17 | $236.25 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 99 | $205.25 |
| 84075 | <1% | 90 | $21.91 | |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 4,733 | $0.00 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 0% | 722 | $0.00 |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 0% | 162 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialNOLAN, JOSEPH (MEDICAL DIRECTOR)